GlaxoSmithKline and Daiichi Sankyo Co., Ltd. have agreed to co-promote Rotarix, GSK’s vaccine to prevent rota-virus gastroenteritis in infants in Japan.
GSK received approval from the regulatory authories to market Rotarix in Japan on July 1, 2011. Rotarix oral liquid formulation is the first vaccine to be approved in Japan for infants to prevent gastroenteritis caused by rotavirus, for which only symptomatic treatment was available until now. The vaccination is completed with two oral doses.
Release Date: July 4, 2011
Source: Daiichi Sankyo Co., Ltd
Filed Under: Drug Discovery